Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF

Abdel-Maksoud, Mohammed S.; Ali, Eslam M.H.; Ammar, Usama M.; Mersal, Karim I.; Yoo, Kyung Ho; Oh, Chang-Hyun

Abstract

Several pyrrolo[2,3-b]pyridine-based B-RAF inhibitors are well known and some of them are currently FDA approved as anticancer agents. Based on the structure of these FDA approved V600E B-RAF inhibitors, two series of pyrrolo[2,3-b]pyridine scaffold were designed and synthesized in attempt to develop new potent V600E B-RAF inhibitors. The 38 synthesized compounds were biologically evaluated for their V600E B-RAF inhibitory effect at single dose (10 μM). Compounds with high percent inhibition were tested to determine their IC 50 over V600E B-RAF. Compounds 34e and 35 showed the highest inhibitory effect with IC 50 values of 0.085 µM and 0.080 µM, respectively. Headed for excessive biological evaluation, the synthesized derivatives were tested over sixty diverse human cancer cell lines. Only compound 35 emerged as a potent cytotoxic agent against different panel of human cancer cell lines.

• Journal Article Type: Article
• Acceptance Date: Apr 5, 2020
• Online Publication Date: Apr 10, 2020
• Publication Date: 2020-06
• Deposit Date: Dec 11, 2022
• Journal: Bioorganic & Medicinal Chemistry
• Print ISSN: 0968-0896
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 28
• Issue: 11
• Article Number: 115493
• DOI: https://doi.org/10.1016/j.bmc.2020.115493
• Keywords: B-RAF inhibitors, Kinase inhibitor, Anticancer, Pyrrolo[2,3-b]pyridine, SAR
• Public URL: http://researchrepository.napier.ac.uk/Output/2982032